Jun. 16 at 7:58 PM
Pelthos Therapeutics shares climbed in afternoon trading after an SEC Form 4 filing revealed that director Todd C. Davis purchased approximately 35,948 shares worth nearly
$1 million on June 11, with the disclosure becoming public on June 15. The transactions were executed at weighted average prices ranging from about
$27.80 to
$28.73 per share. Notably, the purchase was Davis' second-largest across six separate buying episodes, pointing to a pattern of deliberate insider accumulation rather than a one-off investment. The move also came alongside favorable analyst sentiment, with Wall Street maintaining a Strong Buy consensus and an average 12-month price target significantly above current trading levels. Despite a weaker broader market backdrop and pressure across healthcare and small-cap biotech stocks, Pelthos outperformed on company-specific news.
$PTHS